Filtered By:
Specialty: Neuroscience
Condition: Thrombosis
Therapy: Thrombolytic Therapy

This page shows you your search results in order of date.

Order by Relevance | Date

Total 28 results found since Jan 2013.

Modulation of the autophagy ‐lysosomal pathway and endoplasmic reticulum stress by ketone bodies in experimental models of stroke
We report for the first time that the protective effect of β-hydroxybutyrate (BHB) against stroke and glucose deprivation is enantiomer selective. We discovered that D-BHB treatment prevented the cleavage of the lysosomal membrane protein LAMP2, maintained lysosome integrity and stimulated the autophagic flux. Also, D-BHB notably reduced the activation of the PERK and IRE1α branches of the unfolded protein response (UPR), attenuating protein synthesis inhibition and preventing endoplasmic reticulum stress. Together our results support the therapeutic use of D-BHB treatment post-ischemia, by preventing the loss of proteos...
Source: Journal of Neurochemistry - June 17, 2023 Category: Neuroscience Authors: Teresa Montiel, Juan Carlos G ómora‐García, Cristian Gerónimo‐Olvera, Yessica Heras‐Romero, Berenice N. Bernal‐Vicente, Xochitl Pérez‐Martínez, Luis B. Tovar‐y‐Romo, Lourdes Massieu Tags: ORIGINAL ARTICLE Source Type: research

Intra-arterial thrombolytic therapy for acute anterior spinal artery stroke
Publication date: Available online 24 December 2020Source: Journal of Clinical NeuroscienceAuthor(s): Joseph Haynes, Maksim Shapiro, Eytan Raz, Barry Czeisler, Erez Nossek
Source: Journal of Clinical Neuroscience - December 25, 2020 Category: Neuroscience Source Type: research

Inhibition of PI3Kγ by AS605240 plus low-dose tissue plasminogen activator (tPA) combination improves thrombolytic therapy in a rat model of embolic stroke
Publication date: Available online 31 August 2020Source: Neuroscience LettersAuthor(s): Rong Jin, Wei Zhong, Shan Liu, Min Wang, Guohong Li
Source: Neuroscience Letters - September 1, 2020 Category: Neuroscience Source Type: research

A Successful Quality Improvement Project for Detection and Management of Acute Stroke in Hospitalized Patients
CONCLUSION: The new IHS protocol has led to a marked increase in cases identified, rapid evaluation, and high utilization rate of acute stroke therapies.
Source: Journal of Neuroscience Nursing - July 30, 2020 Category: Neuroscience Tags: Clinical Nursing Focus Source Type: research

Thrombolysis beyond 4.5  h in Acute Ischemic Stroke
AbstractPurpose of ReviewThe purpose of this article is to review the current approaches using neuroimaging techniques to expand eligibility for intravenous thrombolytic therapy in acute ischemic stroke patients with stroke of unknown symptom onset.Recent FindingsIn recent years, several randomized, placebo-controlled trials have shown neuroimaging-guided approaches to be feasible in determining eligibility for alteplase beyond 4.5  h from last known well, and efficacious for reducing disability. DWI-FLAIR mismatch on MRI is an effective tool to identify stroke lesions less than 4.5 h in onset in patients with stroke of ...
Source: Current Neurology and Neuroscience Reports - June 29, 2020 Category: Neuroscience Source Type: research

Occludin degradation makes brain microvascular endothelial cells more vulnerable to reperfusion injury in vitro
AbstractIntracerebral hemorrhage is the most dangerous complication in tPA thrombolytic therapy for ischemic stroke, which occurs as a consequence of endothelial cell death at the blood brain barrier (BBB) during thrombolytic reperfusion. We have previously shown that cerebral ischemia induced rapid occludin degradation and BBB disruption. Here we demonstrated an important role of occludin degradation in facilitating the evolution of ischemic endothelial cells towards death. Cultured brain microvascular endothelial cells (bEnd.3 cells) were exposed to oxygen ‐glucose deprivation (OGD) or incubated with occludin siRNA or ...
Source: Journal of Neurochemistry - June 11, 2020 Category: Neuroscience Authors: Yuan Zhang, Xiaofeng Li, Shanshan Qiao, Dexin Yang, Zongyang Li, Ji Xu, Weiping Li, Li Su, Wenlan Liu Tags: ORIGINAL ARTICLE Source Type: research

Assessment of recombinant tissue plasminogen activator (rtPA) toxicity in cultured neural cells and subsequent treatment with poly-arginine peptide R18D.
Abstract Thrombolytic therapy with recombinant tissue plasminogen activator (rtPA) in ischaemic stroke has been associated with neurotoxicity, blood brain barrier (BBB) disruption and intra-cerebral hemorrhage. To examine rtPA cellular toxicity we investigated the effects of rtPA on cell viability in neuronal, astrocyte and brain endothelial cell (bEnd.3) cultures with and without prior exposure to oxygen-glucose deprivation (OGD). In addition, the neuroprotective peptide poly-arginine-18 (R18D; 18-mer of D-arginine) was examined for its ability to reduce rtPA toxicity. Studies demonstrated that a 4- or 24-h expos...
Source: Neurochemical Research - March 4, 2020 Category: Neuroscience Authors: Kenna JE, Anderton RS, Knuckey NW, Meloni BP Tags: Neurochem Res Source Type: research

Rosiglitazone ameliorates tissue plasminogen activator-induced brain hemorrhage after stroke.
CONCLUSIONS: RSG treatment protects against BBB damage and ameliorates HT in delayed tPA-treated stroke mice by activating PPAR-γ and favoring microglial polarization toward anti-inflammatory phenotype. PMID: 31756041 [PubMed - as supplied by publisher]
Source: CNS Neuroscience and Therapeutics - November 21, 2019 Category: Neuroscience Authors: Li Y, Zhu ZY, Lu BW, Huang TT, Zhang YM, Zhou NY, Xuan W, Chen ZA, Wen DX, Yu WF, Li PY Tags: CNS Neurosci Ther Source Type: research

The effect of HMG-CoA reductase inhibitors on thrombolysis-induced haemorrhagic transformation
Publication date: Available online 11 September 2019Source: Journal of Clinical NeuroscienceAuthor(s): Yousheng Wu, Dan Lu, Anding XuAbstractThrombolysis-induced haemorrhagic transformation is the most challenging preventable complication in thrombolytic therapy. This condition is often associated with poor functional outcome and long-term disease burden. Statins, or 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, are controversially suggested to either increase or decrease the odds of better primary outcomes compared to treatment without statins after thrombolysis in patients or animals; statins are ...
Source: Journal of Clinical Neuroscience - September 12, 2019 Category: Neuroscience Source Type: research

Frequency, Risk Factors, and Clinical Significance of Incorrect Dose of Alteplase Due to Weight Estimation in Acute Ischemic Stroke Patients: A Single-Center Retrospective Study
Stroke is a clinical emergency requiring urgent recombinant tissue-type plasminogen activator treatment in eligible patients. The dosage of thrombolytic agent (alteplase) is weight dependent. However, many patients receive thrombolytic therapy based on weight estimation. Here, we assess the frequency of incorrect thrombolytic therapy dose as a result of weight estimation and evaluate the short-term safety and efficacy of alteplase misdose. Of 237 patients, weight was estimated in 147 (62%), of which 33 patients (22.4%) were treated with an erroneous dose of alteplase. An incorrect dose was associated with neither poor outc...
Source: Journal of Neuroscience Nursing - September 9, 2019 Category: Neuroscience Tags: Article Source Type: research

Dl-3-N-Butylphthalide Alleviates the Blood–Brain Barrier Permeability of Focal Cerebral Ischemia Reperfusion in Mice
In conclusion, NBP exerts neuroprotective effects through attenuating cerebral infarct volume and neurological deficit score, reducing cerebral edema and BBB permeability. The neuroprotective effect of NBP is possibly related to its ability to improve blood flow in cerebral ischemic areas. NBP may turn into a novel treatment drug to prevent BBB dysfunction in ischemic stroke.
Source: Neuroscience - June 26, 2019 Category: Neuroscience Source Type: research

Therapeutic strategy against ischemic stroke with the concept of neurovascular unit
Publication date: Available online 1 April 2019Source: Neurochemistry InternationalAuthor(s): Tomohiko Ozaki, Hajime Nakamura, Haruhiko KishimaAbstractStroke is one of the leading causes of death and disability globally. Although thrombolytic therapy by t-PA and mechanical thrombectomy have improved outcomes of ischemic stroke patients, both of these approaches are applicable to limited numbers of patients owing to their time constraints. Therefore, development of other treatment approaches such as developing neuroprotective drugs and nerve regeneration therapy is required to overcome ischemic stroke. The concept of the ne...
Source: Neurochemistry International - April 2, 2019 Category: Neuroscience Source Type: research

Treatment With Intravenous Alteplase for Acute Ischemic Stroke After Reversal of Dabigatran With Idarucizumab: A Case Study
Treatment options for anticoagulated patients presenting with ischemic stroke are limited. Off-label use of idarucizumab to rapidly reverse the anticoagulant effect of dabigatran may ensure eligibility for thrombolytic therapy with alteplase. This case describes a 77-year-old white male who presented to the hospital 89 minutes after sudden onset of right-sided hemiparesis, dysarthria, and facial palsy. Significant history included atrial fibrillation and previous right-sided cortical stroke. Medication reconciliation revealed he was taking dabigatran 150 mg twice a day, with the last dose being 179 minutes before presentat...
Source: Journal of Neuroscience Nursing - January 8, 2019 Category: Neuroscience Tags: Case Study Source Type: research

LDL receptor blockade reduces mortality in a mouse model of ischaemic stroke without improving tissue-type plasminogen activator-induced brain haemorrhage: towards pre-clinical simulation of symptomatic ICH
ConclusionDespite the proven causative relationship between severe HT and neurological deterioration in human stroke, rt-PA-triggered HT in mouse MCAo does not contribute to neurological deficit or simulate sICH. Model limitations, such as the long duration of occlusion required, the type of HT achieved and the timing of deficit assessment may account for this mismatch. Our results further suggest that blockade of LDL receptors improves stroke outcome irrespective of rt-PA, blood –brain barrier breakdown and HT.
Source: Fluids and Barriers of the CNS - November 21, 2017 Category: Neuroscience Source Type: research

Evaluation of functional outcome measured by modified Rankin scale in rtPA treated patients with acute ischemic stroke.
Authors: Georgievski-Brkic B, Savic M, Nikolic D, Nikcevic L, Vukicevic M, Kozic D Abstract Aim of our study was to assess functional outcome measured by modified Rankin scale (mRS) in patients that were treated with thrombolytic therapy-recombinant tissue plasminogen activator (rtPA) after acute ischemic stroke. The study included 100 participants that were treated after acute ischemic stroke. Analyzed parameters included: gender; age groups: age 54 and below (Groupup to-54), 55-64 (Group55-64), 65-74 (Group65-74), and 75 and above (Group75-up); cerebral blood flow (CBF) and cerebral blood volume (CBV). Considerin...
Source: Archives Italiennes de Biologie - March 23, 2017 Category: Neuroscience Tags: Arch Ital Biol Source Type: research